Ohio State Experts Studying New Targeted Therapy for Ovarian Cancer

A new therapy that targets “the machinery” within ovarian cancer cells may well be able to block those cells and turn them off.

Multiple studies underway at the OSUCCC – James studying PARP inhibitors, targeted therapies that impact the DNA of cancer cells, resulting in the replication turning itself off so that the cell dies.

“We are in unprecedented time of new therapies for patients with cancer,” David O’Malley, MD, says. “In the last five years in ovarian cancer, we’ve had as many new drugs in approvals in the United States as we’ve had in the 50 prior years. We are no longer talking about controlling cancer — we’re talking about getting rid of cancer so it doesn’t come back.”